)
Visual
test
Inhalation Sciences
Inhalation Sciences (ISAB) investor relations material
Inhalation Sciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary27 Feb, 2026
Executive summary
Order intake in Q4 2025 reached 5.4 MSEK, significantly higher than the previous year, with most orders to be delivered in 2026.
The company engaged PharmaVentures to explore potential acquisition opportunities.
Several new contracts were signed with international clients, including major pharmaceutical companies and research institutions.
The company continues to focus on commercializing its core technology and expanding its service portfolio.
Financial highlights
Net sales for Q4 2025 were 1,296 tkr, down from 1,492 tkr in Q4 2024; full-year net sales were 3,041 tkr, down from 11,047 tkr.
Operating loss for Q4 2025 was -2,651 tkr (Q4 2024: -2,406 tkr); full-year operating loss was -10,155 tkr (2024: -5,076 tkr).
Cash flow from operations for the year was -11,228 tkr (2024: -3,380 tkr); cash and cash equivalents at year-end were 2,831 tkr.
Equity at year-end was 7,261 tkr, with an equity ratio of 76.2%.
Earnings per share for the year were -0,35 SEK (2024: -0,34 SEK).
Outlook and guidance
The company expects a strong start to 2026 due to a large order backlog.
Ongoing strategic review may result in a sale or partnership within 9-12 months.
No dividend is proposed for 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inhalation Sciences
- Operating profit up 24% in H1 2024, but sales and order intake declined; FDA study nears completion.ISAB
Q2 202423 Jan 2026 - Operating profit up 12% despite lower sales; FDA study and partnerships support outlook.ISABQ3 202413 Jan 2026
- Revenue fell, losses widened, but order intake and cash position improved after new financing.ISABQ3 202521 Nov 2025
- FDA validation of Dissolvate positions the company as a leader in inhalation drug research services.ISABStudy Result12 Nov 2025
- Revenue fell sharply, but cost cuts and new funding support a push toward profitability.ISABQ2 202529 Aug 2025
- Expanded platform, secured grant, and no further capital needed; market remains strong.ISABStatus Update6 Jun 2025
- Record order backlog and FDA validation drive growth plans despite widening losses.ISABQ1 20256 Jun 2025
- Revenue fell and losses widened in 2024, with growth hinging on new sales and financing.ISABQ4 20245 Jun 2025
Next Inhalation Sciences earnings date
Q1 202611 May, 2026
Inhalation Sciences
Next Inhalation Sciences earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage